2021
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience
Lee E, Selig W, Meehan C, Bacha J, Barone A, Bloomquist E, Chang S, de Groot J, Galanis E, Hassan I, Kalidas C, Khasraw M, Kvedar J, Lassman A, Puduvalli V, Sahebjam S, Schwamm L, Tamir S, Welch M, Yung W, Zadeh G, Arons D, Wen P. Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. Neuro-Oncology 2021, 23: 1252-1260. PMID: 33822177, PMCID: PMC8083574, DOI: 10.1093/neuonc/noab082.Peer-Reviewed Original ResearchMeSH KeywordsBrain NeoplasmsCOVID-19HumansNational Cancer Institute (U.S.)SARS-CoV-2United StatesUnited States Food and Drug AdministrationConceptsTumor clinical trialsBrain tumor clinical trialsClinical trialsNational Brain Tumor SocietyCOVID-19 experienceClinical trial designUse of telemedicineNational Cancer InstituteCommunity cliniciansBrain tumor communityNeuro-oncologyTrial designCancer InstituteUS FoodDrug AdministrationPatient advocatesClinical research organizationsTrialsCOVID-19Potential long-term impactLong-term impactReportPatientsCliniciansAdministration
2020
Acute ischemic stroke: improving access to intravenous tissue plasminogen activator
Turner A, Schwamm L, Etherton M. Acute ischemic stroke: improving access to intravenous tissue plasminogen activator. Expert Review Of Cardiovascular Therapy 2020, 18: 277-287. PMID: 32323590, DOI: 10.1080/14779072.2020.1759422.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravenousBrain IschemiaFibrinolytic AgentsHumansStrokeThrombolytic TherapyTissue Plasminogen ActivatorTreatment OutcomeUnited StatesUnited States Food and Drug AdministrationConceptsAcute ischemic strokeIschemic stroke patientsIschemic strokeStroke patientsTreatment windowAcute ischemic stroke patientsIntravenous tissue plasminogen activatorTreatment ratesUnknown symptom onsetAcute stroke careTissue plasminogen activatorQuality improvement initiativesHealth care resourcesUnited States FoodStroke outcomeSymptom onsetStroke careStroke specialistsStroke systemsTelestroke networkDrug AdministrationAlteplasePatientsPlasminogen activatorStates Food
2018
STAIR X
Liebeskind D, Derdeyn C, Wechsler L, Albers G, Ankerud E, Boltze J, Broderick J, Campbell B, Elkind M, En’Wezoh D, Furlan A, Gorelick P, Grotta J, Hess D, Hancock A, Hill M, Holt W, Hutchison R, Kim W, Lansberg M, LaScalza S, Latour L, Liberman M, Luby M, Lyden P, Majidi S, Mansi C, Nogueira R, Saver J, Savitz S, Schwamm L, Selim M, Sheth K, Simpkins A, Singhal A, Solberg Y, Steinberg G, Taylor T, Tymianski M, Yoo A. STAIR X. Stroke 2018, 49: 2241-2247. PMID: 30355006, DOI: 10.1161/strokeaha.118.021424.Peer-Reviewed Original ResearchBiomarkersCerebral AngiographyDevice ApprovalEducationEndovascular ProceduresGuidelines as TopicHumansIntracranial HemorrhagesPrecision MedicineRandomized Controlled Trials as TopicRegistriesResearch DesignStrokeThrombectomyThrombolytic TherapyTreatment OutcomeUnited StatesUnited States Food and Drug Administration